A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphoma kinase (ALK)

ovartis Pharma Services AG0 个研究点目标入组 106 人开始时间: 2015年10月26日最近更新: 2018年9月3日

试验速览

暂无简介。

•- Written informed consent for the main study obtained prior to any screening procedure.
•- Patient must provide an archival or fresh tumor tissue before the first dose of the study drug for ALK testing at a Novartis designated central laboratory by a comparative technology: the confirmation of ALK positivity is not required for enrollment if other inclusion and exclusion criteria are fulfilled
•- Patient is 18 years or older at the time of informed consent.
•- Patient has WHO performance status = 2.
•- Patient has at least one measurable lesion as defined by appropriate guidelines. A lesion at a previously irradiated site may only be counted as a target lesion if there is clear sign of progression since the irradiation
•Other protocol related inclusion criteria may apply
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 75
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 31

•1. Patient with ALK+ lung cancer.
•2. Patient with known hypersensitivity to any of the excipients of LDK378.
•3. Patient with symptomatic CNS metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.
•4. History of carcinomatous meningitis.
•5. Patient with diarrhea CTCAE = grade 2; or patients with neuropathy CTCAE = grade 2
•Other protocol related exclusion criteria may apply.

发起方